We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News Medica 2024 AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

Wearable Sleep Trackers Could Predict Blood Biomarkers of Alzheimer’s Disease in At-Risk Individuals

By HospiMedica International staff writers
Posted on 12 Sep 2024

Sleep disturbances are a common early indicator of Alzheimer’s disease, often occurring before cognitive symptoms become apparent. Traditional sleep assessments, while accurate, are costly and typically capture data from just one night. In an effort to improve early diagnosis, a new five-year study will now explore whether wearable sleep trackers can predict Alzheimer's-related blood biomarkers in individuals at risk.

Researchers at the University of Massachusetts Amherst (Amherst, MA, USA) will investigate whether sleep data collected from wearables can identify patterns linked to future cognitive decline, as indicated by specific blood biomarkers. While wearable devices are not a replacement for clinical diagnostic tools for Alzheimer’s or cognitive changes, they could serve as an early detection tool to identify individuals at risk. The study will focus on participants who have a genetic predisposition to Alzheimer’s disease but are not yet showing cognitive impairment. Participants will wear three types of sleep trackers over the course of a week: the Apple Watch, the Oura Ring, and the CGX Patch, a forehead-worn electroencephalogram (EEG) device that tracks brain activity through metal electrodes.


Image: Wearable sleep trackers and AI could predict early signs of Alzheimer’s (Photo courtesy of 123RF)
Image: Wearable sleep trackers and AI could predict early signs of Alzheimer’s (Photo courtesy of 123RF)

The sleep data collected will be compared to blood tests for amyloid and tau proteins—key early biomarkers of Alzheimer’s. The assessment will be repeated two years later to track any changes. Although blood tests for Alzheimer's are becoming more reliable, identifying which individuals should undergo these tests and see a neurologist remains a challenge. Wearable devices could bridge this diagnostic gap, facilitating early detection of Alzheimer’s disease.

“Many people already wear smartwatches to sleep these days. Imagine receiving an alert from your smartwatch advising you to see a neurologist. That could be the direction we are headed,” said Joyita Dutta, professor of biomedical engineering at the University of Massachusetts Amherst, who will conduct the study. “The project will enable the integration of a wealth of new data — genetic information, wearables-derived metrics, and blood-based biomarkers to create a more comprehensive picture of the sleep-dementia axis.”

Related Links:
University of Massachusetts Amherst


New
Gold Member
X-Ray QA Meter
T3 AD Pro
Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
New
Standing Sling
Sara Flex
New
Mobile Barrier
Tilted Mobile Leaded Barrier

Latest Critical Care News

Ablation Treatment Better Than Medication for Heart Attack Survivors

Cranial Accelerometry Headset Enables Timely and Accurate Prehospital Detection of LVO Strokes

Ingestible Capsule Pump Drugs Directly into Walls of GI Tract